OR WAIT null SECS
Medidata & Tufts Center for the Study of Drug Development announced results of a study on the impact of protocol amendmends made while a clinical trial is underway. The study discussed their avoidability, costs and time delays.
Read the full release here
Read more in Kenneth Getz’s column this month here